SCHEMBL933757

SCHEMBL933757

Cc1ccc(SC(C(=O)O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
HSD17B10 Q99714 1/20 0.54
POLB P06746 1/20 0.49
TRPA1 O75762 1/20 0.48
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
LMNA P02545 4/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
CNR2 P34972 1/20 0.42
PPARA Q07869 2/20 0.41
PPARG P37231 1/20 0.41
MMP2 P08253 1/20 0.41
MMP8 P22894 1/20 0.41
MMP14 P50281 1/20 0.41
TSHR P16473 1/20 0.41
THRB P10828 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521016 0.92 CYP2C9 (0.63) CYP2C9CYP2C19HSD17B10TRPA1LMNA
SCHEMBL6788461 0.85 CYP2C9 (0.56) CYP2C9CYP2C19HSD17B10TRPA1LMNA
SCHEMBL11563095 0.85 CYP2C9 (0.55) CYP2C9CYP2C19HSD17B10POLBTRPA1
SCHEMBL29283515 0.85 LMNA (0.56) POLBLMNAALDH1A1MAPTKMT2A
SCHEMBL1565683 0.85 LMNA (0.56) POLBLMNAALDH1A1MAPTKMT2A
SCHEMBL11562132 0.85 CYP2C9 (0.59) CYP2C9CYP2C19HSD17B10POLBTRPA1
SCHEMBL28703755 0.85 CYP2C9 (0.59) CYP2C9CYP2C19HSD17B10POLBTRPA1
SCHEMBL27599627 0.84 KMT2A (0.44) LMNAALDH1A1MAPTKMT2APPARA
SCHEMBL933879 0.84 CYP2C9 (0.54) CYP2C9CYP2C19HSD17B10TRPA1LMNA
SCHEMBL11761904 0.83 TRPA1 (0.51) CYP2C9CYP2C19HSD17B10TRPA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 CYP2C9 2965/4885CYP2C19 2153/4885HSD17B10 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.